tirzepatide and semaglutide mechanism of action of tirzepatide GIP = glucose-dependent insulinotropic polypeptide; GLP-1 = glucagon-like peptide 1; LDL = low-density lipoprotein; HR = heart rate Assessing the Safety of Semaglutide

It stems from GLP-1 receptors in the gut and brainstem that slow gastric emptying and amplify satiety signals the same mechanism responsible for reduced appetite and weight loss

Both have gained popularity due to their effectiveness, but its important to understand their differences and similarities to better prepare you for conversations with a licensed medical provider about whether these medications are right for you

Add moderate cardio (2-3 sessions weekly) as supplemental activity

Currently, the FDA guidelines state that to be considered for a GLP-1 agonist, individuals must have: A BMI of 30 or greater OR A BMI of 27 or greater with at least one weight-related comorbidity (i.e

y l sn phm bn chy ti Hn Quc thi gian qua, v ang rt HOT trn th trng